Short answer
Akebia Therapeutics, Inc. (AKBA) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $59M (up 57.0% year over year) with net income of $540,000.
Q3 2025 key financials · XBRL
- Revenue
- $59M
- +57.0% YoY · −5.9% QoQ
- Net income
- $540,000
- +102.7% YoY · +118.6% QoQ
- Operating margin
- 7.6%
- EPS (diluted)
- $0.01
- +111.1% YoY · +200.0% QoQ
Source: XBRL data from the Akebia Therapeutics, Inc. (AKBA) Q3 2025 10-Q on SEC EDGAR. USD.
Akebia Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Vafseo shipments began January 2025; U.S. market opportunity approximately $1 billion
- Auryxia lost exclusivity March 2025, with authorized generic competition beginning thereafter
- R&D expenses $1.7 billion cumulatively through September 30, 2025
- VALOR trial not planned after FDA feedback; no broad Vafseo non-dialysis label expected
Risk Factors
- Auryxia generic competition risk intensified after loss of exclusivity in March 2025
- Vafseo commercialization risk increased through narrower FDA approval and delayed launch
- Vifor repayment exposure began July 2025, with 8%–14% royalties and $10.0 million minimum payment due May 31, 2026
- Profitability risk persists despite $0.5 million quarterly net income and $1.7 billion accumulated deficit
- Debt risk includes $55.0 million of BlackRock term loans requiring repayment under the credit agreement
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Akebia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.